Combined oral contraceptive use and obesity in women with polycystic ovary syndrome. A meta-analysis of randomized clinical trials.

Autor: de Medeiros SF; Department of Gynecology and Obstetrics, Medical School, Federal University of Mato Grosso, Cuiabá, MT, Zip code 78 043 306, Brazil. de.medeiros@terra.com.br.; Tropical Institute of Reproductive Medicine, Cuiabá, MT, Brazil. de.medeiros@terra.com.br., Junior JMS; Disciplina de Ginecologia, University of São Paulo, São Paulo, Brazil., de Medeiros MAS; Tropical Institute of Reproductive Medicine, Cuiabá, MT, Brazil., Yamamoto AKLW; Tropical Institute of Reproductive Medicine, Cuiabá, MT, Brazil.; University of Cuiabá, Cuiabá, MT, Brazil., de Medeiros CLW; University of Cuiabá, Cuiabá, MT, Brazil., da Silva Carvalho AB; Tropical Institute of Reproductive Medicine, Cuiabá, MT, Brazil., Yamamoto MMW; Tropical Institute of Reproductive Medicine, Cuiabá, MT, Brazil., Baracat EC; Disciplina de Ginecologia, University of São Paulo, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: Archives of gynecology and obstetrics [Arch Gynecol Obstet] 2024 Oct; Vol. 310 (4), pp. 2223-2233. Date of Electronic Publication: 2024 Jul 18.
DOI: 10.1007/s00404-024-07637-5
Abstrakt: Background: Polycystic ovary syndrome (PCOS) is a heterogenous endocrine condition and combined oral contraceptives (COCs) have been demonstrated to be the first-line treatment to women who do not intend to become pregnant. The combination of COCs and PCOS may or may not amplify the risks of cardiovascular events.
Objective: To investigate whether surrogates for obesity may be influenced by the use of COCs containing different formulations in women with PCOS.
Method: From January 2024 a literature search was conducted in Google Scholar and Pubmed databases using PCOS, COC, and obesity terms. Hand search of randomized clinical trials in the references of obtained manuscripts was also performed. After the exclusion of reviews and articles that did not fulfill eligibility criteria, compared the results obtained before and after the use of COCs in 13 randomized clinical trials (RCTs). Random-effects model was used to estimate the standardized mean differences (SMD) and standard errors (SE). Risk of bias was examined using the Rob2 tool.
Result: Thirteen heterogeneous RCTs reported no difference in waist circumference with the use of different COC formulations (p = 0.714). On the contrary, body fat mass increased with the use of pill (p = 0.013). Waist triglyceride index and lipid accumulation product tended to be higher after the use of COCs (p = 0.073 and p = 0.064, respectively).
Conclusion: Combined oral contraceptives with different formulations might increase fat mass accumulation in women with PCOS. Lipids may also be increased in PCOS users. Because some concerns about the quality and heterogeneity identified in various RCTs, caution should be taken before a definitive conclusion regarding the use of COCs and obesity.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: